<qa>  What is the first-line therapy for HER2 positive locally advanced or metastatic breast cancerOverall Survival data on patients who have progressed following the combination of Trastuzumab and Docetaxel with or without capecitabine as first-line therapy for HER2 positive locally advanced or metastatic breast cancer will also be analysed and reported. 